Safety and immunogenicity of a new Neisseria meningitidis serogroup C- tetanus toxoid conjugate vaccine in healthy adults

Peter Richmond*, David Goldblatt, Peter C. Fusco, Joan D.S. Fusco, Iver Heron, Sarah Clark, Raymond Borrow, Francis Michon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

83 Citations (Scopus)

Abstract

We evaluated the safety and immunogenicity of a single dose of a new serogroup C O-deacetylated meningococcal polysaccharide-tetanus toxoid conjugate vaccine in 30 healthy adult volunteers. The vaccine was well tolerated with no serious adverse events and minimal local reactions and systemic symptoms. All subjects developed a fourfold or greater increase in serum bactericidal antibody (SBA) to serogroup C meningococcus. SBA geometric mean titre increased from 11 to 3649 (p < 0.001). Serogroup C-specific IgG levels increased postvaccination from 0.65 to 17.02 μg/ml (p < 0.001). Bactericidal titres pre- and postimmunisation showed significant correlation with serogroup C-specific IgG (r2=0.693). Antibody levels fell by 6 months postvaccination, however, meningococcal C IgG avidity increased indicating the successful induction of a T-cell-dependent antibody response. Conclusion: meningococcal C-tetanus toxoid conjugate vaccine is immunogenic and well tolerated in healthy adults.

Original languageEnglish
Pages (from-to)641-646
Number of pages6
JournalVaccine
Volume18
Issue number7-8
DOIs
Publication statusPublished - 12 Nov 1999

Keywords

  • Avidity
  • Conjugate vaccine
  • Polysaccharide
  • Serogroup C meningococcus

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of a new Neisseria meningitidis serogroup C- tetanus toxoid conjugate vaccine in healthy adults'. Together they form a unique fingerprint.

Cite this